- CA$63.16m
- CA$78.46m
- CA$0.41m
- 28
- 13
- 57
- 24
Annual income statement for MedMira, fiscal year end - July 31st, CAD millions except per share, conversion factor applied.
2020 July 31st | 2021 July 31st | 2022 July 31st | 2023 July 31st | 2024 July 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.919 | 2.14 | 0.952 | 0.433 | 0.413 |
| Cost of Revenue | |||||
| Gross Profit | 0.572 | 1.72 | 0.304 | 0.3 | 0.226 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 2.22 | 2.14 | 2.22 | 2.21 | 2.84 |
| Operating Profit | -1.3 | 0.006 | -1.27 | -1.78 | -2.43 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -2.05 | -0.676 | -1.83 | -2.68 | -3.33 |
| Net Income After Taxes | -2.05 | -0.676 | -1.83 | -2.68 | -3.33 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -2.05 | -0.676 | -1.83 | -2.68 | -3.33 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -2.05 | -0.676 | -1.83 | -2.68 | -3.33 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.003 | -0.001 | -0.003 | -0.004 | -0.005 |